EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study

Isotta Giunipero di Corteranzo iD, Eleonora Bongiovanni iD, Stephano Cedirian iD, Michela Starace, Bianca Maria Piraccini, Luca Mastorino iD, Pietro Quaglino, Simone Ribero, Giuseppe Gallo

International Journal of Dermatology · 2025-07 · 64 (7) · 1242-1245

DOI: 10.1111/ijd.17732 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Dermatology, online erschienen am 21.03.2025. Verfasst von Isotta Giunipero di Corteranzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Alopecia Areata, Azetidines, Sulfonamides, Pyrazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In adults, baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the first globally approved treatment for severe alopecia areata (AA). Its efficacy and safety were established in phase III trials, but real‐life evidence remains limited.

Objective

Our aim was to evaluate the real‐life safety profile of baricitinib over 48 weeks in a clinical setting.

Methods

A prospective observational study was conducted on 87 adult patients with severe AA at the University Hospital of Turin. Patients were treated with baricitinib at doses of 2 or 4 mg daily and were evaluated at baseline, 12, 24, 36, and 48 weeks. Adverse events (AEs) were carefully monitored, and disease severity was measured using the Severity of Alopecia Tool (SALT) score.

Results

The cohort consisted of 71% females, with a mean age of 42 years and a mean baseline SALT score of 76.9. Baricitinib was generally well tolerated, with 20% of patients reporting AEs. The most common AEs were hypercholesterolemia (17%), hypertriglyceridemia (9.2%), and upper respiratory tract infections (5%). Two patients discontinued treatment due to neutropenia and recurrent infections. Most AEs were mild and manageable.

Conclusion

Baricitinib shows a favorable safety profile in real‐life clinical settings, aligning with findings from controlled clinical trials. The results support its use in routine clinical practice, though larger prospective studies are needed for further confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAzetidinesSulfonamidesPyrazolesJanus Kinase InhibitorsHumansPurinesFemaleAdultMaleProspective StudiesMiddle AgedSeverity of Illness IndexYoung AdultTreatment OutcomeHypercholesterolemiaAged

Stichwörter der Autor:innen

JAK inhibitorsadverse eventsalopecia areatabaricitinibsafety

Substanzen

baricitinibPurinesAzetidinesSulfonamidesPyrazolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.

ORCID-Profile: Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Stephano Cedirian, Luca Mastorino

Zitieren

APA

di Corteranzo, I. G., Bongiovanni, E., Cedirian, S., Starace, M., Piraccini, B. M., Mastorino, L., Quaglino, P., Ribero, S., & Gallo, G. (2025). Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study. International Journal of Dermatology, 64(7), 1242-1245. https://doi.org/10.1111/ijd.17732

Vancouver

di Corteranzo IG, Bongiovanni E, Cedirian S, Starace M, Piraccini BM, Mastorino L, et al. Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study. International Journal of Dermatology. 2025;64(7):1242-1245. doi:10.1111/ijd.17732

BibTeX
@article{diCorteranzo2025,
  author = {di Corteranzo, Isotta Giunipero and Bongiovanni, Eleonora and Cedirian, Stephano and Starace, Michela and Piraccini, Bianca Maria and Mastorino, Luca and Quaglino, Pietro and Ribero, Simone and Gallo, Giuseppe},
  title = {Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study},
  journal = {International Journal of Dermatology},
  year = {2025},
  volume = {64},
  number = {7},
  pages = {1242--1245},
  doi = {10.1111/ijd.17732}
}
Kostenlos starten →